| Title |
The Pharmacologic Management of Delirium in Children and Adolescents
|
|---|---|
| Published in |
Pediatric Drugs, June 2014
|
| DOI | 10.1007/s40272-014-0078-0 |
| Pubmed ID | |
| Authors |
Susan Beckwitt Turkel, Alan Hanft |
| Abstract |
Delirium is a serious and common problem in severely medically ill patients of all ages. It has been less addressed in children and adolescents. Treatment of delirium is predicated on addressing its underlying cause. The management of its symptoms depends on the off-label use of antipsychotics, while avoiding agents that precipitate or worsen delirium. Olanzapine, quetiapine, and risperidone are presently considered first-line drugs, usually replacing haloperidol. Other agents have shown promise, including melatonin to address the sleep disturbance characteristic of delirium, and dexmedetomidine, an α2-agonist, that may facilitate lower doses of benzodiazepines and opioids that may worsen delirium. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 67% |
| United States | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 67% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| Unknown | 100 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 16 | 16% |
| Student > Postgraduate | 15 | 15% |
| Student > Master | 10 | 10% |
| Researcher | 9 | 9% |
| Student > Bachelor | 8 | 8% |
| Other | 25 | 25% |
| Unknown | 18 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 46 | 46% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 9% |
| Nursing and Health Professions | 6 | 6% |
| Agricultural and Biological Sciences | 4 | 4% |
| Business, Management and Accounting | 3 | 3% |
| Other | 9 | 9% |
| Unknown | 24 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 January 2019.
All research outputs
#16,218,580
of 25,626,416 outputs
Outputs from Pediatric Drugs
#399
of 585 outputs
Outputs of similar age
#132,090
of 242,636 outputs
Outputs of similar age from Pediatric Drugs
#4
of 7 outputs
Altmetric has tracked 25,626,416 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 585 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 242,636 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.